2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Elisavet Paplomata, MD, discusses the role of tucatinib in combination with trastuzumab and capecitabine in HER2-positive metastatic breast cancer.
Elisavet Paplomata, MD, assistant professor, University of Wisconsin School of Medicine and Public Health, oncologist, University of Wisconsin Carbone Cancer Center, discusses the role of tucatinib (Tukysa) in combination with trastuzumab (Herceptin) and capecitabine in HER2-positive metastatic breast cancer.
For patients with HER2-positive metastatic breast cancer who progress on second-line ado-trastuzumab emtansine (Kadcyla; T-DM1), the tucatinib-based regimen is a potential third-line option, Paplomata says.
Notably, as displayed in the phase 2 HER2CLIMB trial, this regimen is well tolerated and has a manageable safety profile, Paplomata explains. Approximately 80% of patients experienced diarrhea with the combination, but the toxicity was well managed with antidiarrheal medication.
Additionally, elevated liver enzymes, which were reported in some patients, were well managed with dose interruptions and reductions, adds Paplomata.
The triplet also demonstrated encouraging efficacy in patients with brain metastases and should be considered for patients in that setting, Paplomata concludes.